Antigen-expressed recombinant Salmonella typhimurium driven by an in vivo-activated promoter is capable of inducing cellular immune response in transgenic mice

Acta Biochimica et Biophysica Sinica

Volumn 35, Issue 8, 2003, Pages 695-701

  Wang, Hong Wei ^a   Zhang, Min ^a   Luan, Jie ^a   Hu, Wei Jiang ^a   Zhao, Ping ^a   Gao, Jun ^a   Qi, Zhong Tian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive transfer; Attenuated Salmonella typhimurium; Hepatitis G virus; Immune tolerance; PpagC; Transgenic mouse

Indexed keywords

GAMMA INTERFERON; HEPATITIS G VACCINE; HEPATITIS G VIRUS ANTIBODY; HEPATITIS G VIRUS ANTIGEN; LIVE VACCINE; MESSENGER RNA; SL 7207; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS RNA; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EXPRESSION VECTOR; GENE ACTIVATION; HEPATITIS G; HEPATITIS G VIRUS; HISTOLOGY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LIVER; MOUSE; NONHUMAN; PROMOTER REGION; RNA TRANSCRIPTION; SALMONELLA TYPHIMURIUM; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; VIRUS PATHOGENESIS;

ADOPTIVE TRANSFER; ANIMALS; CYTOKINES; GB VIRUS C; HEPATITIS ANTIGENS; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; RNA HELICASES; SALMONELLA TYPHIMURIUM; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES; VIRAL NONSTRUCTURAL PROTEINS;

ANIMALIA; GB VIRUS C/HEPATITIS G VIRUS; MUS MUSCULUS; RNA VIRUSES; SALMONELLA TYPHIMURIUM; VECTORS;

EID: 0141494331     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Akbar SK, Onji M. Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection. Int J Exp Pathol, 1998, 79 (5): 279-291
2. Koike K, Moriya K, Kimura S. Role of hepatitis C virus in the development of hepatocellular carcinoma: Transgenic approach to viral hepatocarcinogenesis. J Gastroenterol Hepatol, 2002; 17 (4): 394-400
3. Wieland SF, Vega RG, Muller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG et al. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol, 2003, 77 (2): 1227-1236
4. Wang EJ, Pettoello-Mantovani M, Anderson CM, Osiecki K, Moskowitz D, Goldstein H. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells. J Infect Dis, 2002, 186 (10): 1412-1421
5. Hu WJ, Li JX, Wang HW, Hu YP, Qi ZT. Production of transgenic mouse harboring full-length hepatitis G virus genome. Acad J Sec Mil Med Univ, 2002, 23(11): 1175-1178
6. Niethammer AG, Primus FJ, Xiang R, Dolman CS, Ruehlmann JM, Ba Y, Gillies SD et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine, 2001, 20 (3-4): 421-429
7. Chen H, Schifferli DM. Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector. Vaccine, 2001, 19 (20-22): 3009-3018
8. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev, 2002, 26 (4): 339-353
9. Gunn JS, Alpuche-Aranda CM, Loomis WP, Belden WJ, Miller SI. Characterization of the Salmonella typhimurium pagC/pagD chromosomal region. J Bacteriol, 1995, 177 (17): 5040-5047
10. Hitchen PG, Prior JL, Oyston PC, Panico M, Wren BW, Titball RW, Morris HR et al. Structural characterization of lipo-oligosaccharide (LOS) from Yersinia pestis: Regulation of LOS structure by the PhoPQ system. Mol Microbiol, 2002, 44 (6): 1637-1650
11. Beuzón CR, Unsworth KE, Holden DW. In vivo genetic analysis indicates that PhoP-PhoQ and the Salmonella pathogenicity island 2 type III secretion system contribute independently to Salmonella enterica serovar typhimurium virulence. Infect Immun, 2001, 69 (12): 7254-7261
12. Dunstan SJ, Simmons CP, Strugnell RA. Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. typhimurium. Infect Immun, 1999, 67 (10): 5133-5141
13. Hohmann EL, Oletta CA, Loomis WP, Miller SI. Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity. Proc Natl Acad Sci USA, 1995, 92 (7): 2904-2098
14. 2+ sensor PhoQ of Salmonella enterica. J Mol Biol, 2003, 325 (4): 795-807
15. 2+ sensing. J Bacteriol, 2002, 184 (19): 5468-5478
16. Wang HW, Zh P, Zh M, Zhu SY, Qi ZT. Cloning and functional analysis of promoter pagC from attenuated Salmonella typhimurium. Acta Microbiolog Sin, 2003, 43 (3): 8-14
17. Qi ZT, Ren H, Zhu FL, Shao L, Pan W, Hu WJ, He JW et al. Construction and identification of a single stranded cDNA clone containing full-length genome of hepatitis G virus. Ross Gastroenterol Zh, 2001, (2): 46-56
18. Zhu FL, RH, Shong YB, Qi ZT. Expression of GBV-C/HGV NS3 protein in Escherichia coli. Chin J Microbiol Immunol, 1999, 19 (6): 475-478
19. Schmolke S, Tacke M, Schmitt U, Engel AM, Ofenloch-Haehnle B. Identification of hepatitis G virus particles in human serum by E2-specific monoclonal antibodies generated by DNA immunization. J Virol, 1998, 72(5): 4541-4545
20. Zhao P, Zhao LJ, Cao J, Hong HY, Qi ZT. Enhancement of immune responses of hepatitis B virus core DNA vaccine by a signal peptide and a universal helper T lymphocyte epitope. Acta Biochim Biophys Sin, 2002, 34 (3): 341-346
21. Zhao P, Ke SH, Wang HW, Qian F, Qi ZT. Enhancement by an in vivo-activated promoter of immunogenicity of recombinant attenuated Salmonella typhimurium expressing hepatitis C virus core antigen. Acta Biochim Biophys Sin, 2003, 35 (3): 266-270
22. Gwack Y, Yoo H, Song I, Choe J, Hall JH. RNA-stimulated ATPase and RNA helicase activities and RNA binding domain of hepatitis G virus nonstructural protein 3. J Virol, 1999, 73 (4): 2909-2915
23. Wright-Minogue J, Yao N, Zhang R, Butkiewicz NJ, Baroudy BM, Lau JY, Hong Z. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors. J Hepatol, 2000, 32 (3): 497-504
24. Lee YJ, Kang H, Rho SH, Eom SH, Park WJ. Assessment of substrate specificity of hepatitis G virus NS3 protease by a genetic method. Biochem Biophys Res Commun, 2001, 286 (1): 171-175
25. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology, 1991, 183(1): 1-11
26. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA, 1996, 93(22): 12496-12501
27. Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter hemophilia cohort study. Ann Intern Med, 2000, 132(12): 959-963
28. + lymphocyte counts on GB virus C/hepatitis G virus carriership in HIV-positive individuals. J Med Virol, 1999, 57 (4): 367-369